57 results about "Cortisone" patented technology

The invention discloses a progesterone 5beta-reductase mutant and application thereof in synthesis of 5beta-dihydrosteroid, relates to the technical field of biology, and in particular relates to application of gene mining and engineering modification of progesterone 5beta-reductase derived from bacteria in asymmetric synthesis of 5beta-dihydrosteroid. According to the progesterone 5 beta-reductase LpP5beta R disclosed by the invention, the progesterone 5 beta-reductase LpP5beta R from bacteria psoromais is obtained by a gene mining method, and the progesterone 5 beta-reductase LpP5beta R can be subjected to soluble expression in escherichia coli. The mutant obtained by mutating the wild type LpP5beta R has obviously improved catalytic ability on progesterone, and can efficiently catalyze delta 4-3-carbonyl steroids such as hydrocortisone, dinorcitol and the like to generate corresponding 5beta-dihydrosteroids. According to the invention, the technical bottlenecks of poor heterologous expression and low catalytic efficiency of plant-derived progesterone 5beta-reductase are solved, and a potential biocatalyst is provided for green manufacturing of 5beta-dihydrosteroid drugs.

The invention relates to the technical field of medical detection, in particular to a method for detecting aldosterone, cortisol, deoxycorticosterone and cortisone in plasma through LC-MS / MS. The method comprises the following steps: (a) mixing a plasma sample with an internal standard solution to obtain a mixed solution; (b) adding the mixed solution into the magnetic bead suspension, sequentially carrying out adsorption, weak washing, strong washing and elution, and collecting an eluent; (c) carrying out liquid nitrogen blowing and redissolving on the eluent, and then carrying out LC-MS / MS detection; wherein the surfaces of the magnetic beads are modified with steroid adsorption groups, and the target detection objects are aldosterone, cortisol, deoxycorticosterone and cortisone. The detection method is convenient and simple, the detection efficiency is higher than that of a traditional method, and a feasible solution is provided for promoting popularization and application of the LC-MS / MS technology in clinical practice.

This disclosure provides a method for treating hair loss in a subject requiring treatment for hair loss, comprising topically administering an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil to the subject. This disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The invention discloses a preparation method of fluorohydrocortisone acetate, and belongs to the technical field of medicine synthesis. According to the method, the fluorine hydrocortisone acetate is obtained through one-step reaction by taking the Anecortisone acetate as an initial raw material and taking a mixture of an organic solvent and water as a solvent under the condition of a Fe (III) reagent and a fluorine reagent. The preparation method disclosed by the invention is simple and convenient to operate, high in safety, mild in reaction condition, low in cost, high in yield, small in corrosivity and suitable for industrial mass production; meanwhile, the problems that in the prior art, operation is inconvenient, corrosivity is high, toxicity is large, dangerousness is high, the requirement for equipment is high, and the yield is low are solved, and a new technical scheme more suitable for industrial production is provided.

The present disclosure provides methods of treating skin acne-like rash in a subject in need thereof. The method comprises applying an effective amount of picosterone-17 alpha-propionate to the surface of the subject. The acne-like rash may include papules, pustules, nodules, scabs, cysts, or any combination thereof on an affected area of the subject. An effective amount of the picosterone-17 [alpha]-propionate can be administered in a surface pharmaceutical formulation comprising the picosterone-17 [alpha]-propionate and one or more pharmaceutically acceptable carriers.

The invention provides a 3-hydroxypyrone derivative as well as a preparation method and application thereof, the compound can effectively inhibit release of proinflammatory cytokines in lipopolysaccharide-induced microglial cells, inhibit release of NO by the lipopolysaccharide-induced microglial cells, inhibit apoptosis of polysaccharide-induced microglial cells, and inhibit apoptosis of lipopolysaccharide-induced microglial cells. The compound has excellent anti-neuroinflammation activity and neuroprotective effect, the activity of the compound is superior to that of positive controls such as curcumin and hydrocortisone, and the compound can be used for preventing and / or treating neuroinflammation and neurodegenerative diseases.

The invention discloses a construction method of a pulmonary arterial hypertension traditional Chinese medicine syndrome model, and aims to simulate a pulmonary arterial hypertension animal model with syndrome characteristics of heart-kidney yang deficiency. The method comprises the following steps: inducing rat pulmonary arterial hypertension pathological basis by adopting monocrotaline, and inducing a heart-kidney yang deficiency state in combination with hydrocortisone intervention from the 15th day; the characteristics of the model are evaluated through multiple indexes such as echocardiography, blood gas analysis, tri-gland axis hormone, energy metabolism, renal functions, biochemical factors, HE staining and ultrastructure observation. Results show that the model has pathological changes of pulmonary arterial hypertension and syndromes such as yang deficiency, water retention, life gate fire decline and the like in traditional Chinese medicine, the construction method is stable and repeatable, and the model is suitable for an experimental platform for traditional Chinese medicine intervention research and combination of traditional Chinese medicine and western medicine.

The invention provides a special culture medium for prostate cancer organoid and a culture method thereof, and belongs to the technical field of biological medicines. The special culture medium for the prostatic cancer organoid is composed of a basic culture medium and a culture additive, and the basic culture medium does not contain exogenously added Noggin recombinant protein and R-spondin recombinant protein. The culture additive is prepared from a basic fibroblast growth factor, a keratinocyte growth factor, a fibroblast growth factor 10, insulin, a p38MAPK signal channel inhibitor, an insulin-like growth factor 1, B27, nicotinamide, N-acetylcysteine, hydrocortisone, a ROCK kinase inhibitor, retinoic acid, interleukin 6, prostaglandin E2, a eriocin and androgen. According to the special culture medium for the prostatic cancer organoid, the culture success rate is increased while the cost is reduced.

The application relates to the technical field of animal model construction, in particular to a construction method and application of a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model. The construction method comprises the following steps: a model group animal is subjected to modeling by adopting the method of senna leaf water decoction gavage and hydrocortisone and cyclophosphamide injection, and a spleen-kidney yang deficiency syndrome ovarian reserve function decline animal model is obtained. In the application, the three of senna leaf, hydrocortisone and cyclophosphamide are used in synergy to administer the animal model, and the complex syndrome of the clinical spleen-kidney yang deficiency type DOR is accurately reproduced, and modern scientific basis is provided for the theories of traditional Chinese medicine such as the same treatment for different diseases.

This invention relates to novel compounds of the Formula (1m1) wherein R1, R2, R3, A1, Cy1 and E are as defined in the specification, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds for use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Orodispersible film (ODF) is an innovative drug formulation that allows for adjustable dosing and improved patient compliance. It is administered into the mouth where it dissolves, making it suitable for children. The present invention provides an optimized ODF gel formulation and an optimal ODF containing therapeutic doses of hydrocortisone-type corticosteroids (HTC). This ODF is thin, flexible and transparent, and suitable for production in hospital pharmacy using standard equipment. The ODF of the invention allows accurate hydrocortisone levels to be released systemically in patients in need thereof, and its good physico-chemical stability is herein demonstrated for several months. This opens up new opportunities for use in pediatric patients, notably for children suffering from congenital adrenal hyperplasia.

The application discloses a steroid C14 alpha hydroxylase CLCYP14 mutant, relates to the field of proteins, and applies a site-directed saturation mutation technology and a combination mutation strategy to screen and obtain CLCYP14 mutants I111L-M115K and I111L-V124W with high hydroxylation specificity. Compared with CLCYP14, the hydroxylation selectivity and conversion rate of I111L-M115K and I111L-V124W for steroid compounds progesterone, 21-hydroxyprogesterone, 5beta-hydroxyprogesterone, 1-dehydroprogesterone, 21-hydroxypregna-1,4-diene-3,20-dione and deoxycortisone are obviously improved.

This invention relates to a method for constructing and evaluating an animal model of Alzheimer's disease characterized by deficiency and blood stasis. Based on APP / PS1 mice, the model was induced by sleep deprivation, hydrocortisone, and carrageenan to induce qi deficiency, kidney deficiency, and blood stasis, respectively, for a total modeling period of 28 days, resulting in an animal model of Alzheimer's disease with deficiency and blood stasis. This model was constructed using a multi-factor combined approach, and its symptom manifestations are consistent with clinical observations. It is simple, effective, and easy to operate, providing a reliable experimental vehicle for the development of innovative drugs and the study of mechanisms of action in Alzheimer's disease with deficiency and blood stasis.

The application provides a culture medium and a culture method of a gastric cancer organoid. The culture medium comprises an MST1 / 2 kinase inhibitor, a fibroblast growth factor 7, R-spondin 1, hydrocortisone, a B27 supplement, an N2 supplement, insulin, a dual regulatory protein, at least one Rho protein kinase inhibitor selected from Y27632, fasudil and H-1152, forskolin, gastrin, fetal bovine serum and cholera toxin. Compared with the existing culture method, the in-vitro culture using the culture medium has higher amplification efficiency; the culture of the gastric cancer organoid using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the gastric cancer organoid culture.

The present application relates to a culture method and culture medium for reducing the number of epithelial organoids and in vivo tissue differential transcripts, which solves the technical problems of low growth rate and low formation rate of organoids in the prior art. The epithelial organoid culture medium contains basic components and additional components. The basic components contain DMEM / F12 basic medium, penicillin-streptomycin solution, Glutamax additive, recombinant vertebral protein, recombinant cephalopod protein, Y-27632, epidermal growth factor, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer solution, nicotinamide, A83-01 and CHIR99021. The additional components contain Wnt-3A, ITS-X additive and hydrocortisone. The present application simultaneously provides a culture method for epithelial organoids. The present application can be used for the culture of epithelial organoids.

Provided herein are oral liquid formulations of hydrocortisone. Also provided herein are methods of making and using hydrocortisone oral liquid compositions for the treatment of certain diseases including endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, and others.

The present invention discloses a carbonyl reductase mutant and its application in synthesizing 11β-hydroxysteroid compounds. Carbonyl reductase derived from Homo sapiens is modified by semi-rational design methods to provide a carbonyl reductase mutant. The mutant can efficiently catalyze the synthesis of 11β-hydroxysteroid compounds prednisolone, hydrocortisone and methylprednisolone using prednisone, cortisone and methylprednisolone as substrates.

The invention discloses a hydrocortisone compound ointment preparation for treating haemorrhoids, and belongs to the technical field of medicines. The technical problem to be solved is to provide a hydrocortisone compound ointment preparation which has a good hemorrhoid treatment effect and is stable. The hydrocortisone compound ointment preparation comprises the following components in percentage by weight: 0.15%-1% of corticoid, 0.025%-0.1% of a vasoconstrictor, 2%-4% of a local anesthetic, 0.1%-1.5% of L-menthol, 0.02%-0.5% of chlorhexidine acetate and 0.05%-1% of allantoin. The hydrocortisone compound ointment preparation disclosed by the invention has the medicinal effects of relieving pain and discomfort of patients suffering from haemorrhoids, promoting healing and repairing of haemorrhoids tissues, preventing infection and relieving inflammatory response, and has obvious effects of stopping bleeding and relieving swelling and pain in haemorrhoids treatment.

The present invention provides a culture medium and a culture method for primary mesothelial cells. The culture medium comprises a basal culture medium and one or more additives selected from the group consisting of a Rho proteinase inhibitor, epidermal growth factor, hydrocortisone, a glutamine additive, amphiregulin, pancreatic transferrin, and fetal bovine serum. The use of the culture medium for primary mesothelial cells of the present invention creates a more suitable living environment for the growth and reproduction of primary mesothelial cells, thereby significantly improving the culture success rate and expansion rate of primary mesothelial cells.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

The application discloses a P450 enzyme mutant, a coding gene and application thereof in preparation of cortisone, and belongs to the technical field of bioengineering. The P450 enzyme mutant is obtained by amino acid mutation of CYP11B1 from Homo sapiens with an amino acid sequence shown as SEQ ID NO. 1, and the amino acid mutation site is at least one of S146V, H331D and L440F. The P450 enzyme mutant provided by the application has a higher soluble expression level in Escherichia coli than wild-type CYP11B1, the catalytic level of the constructed recombinant expression strain is higher, 11-deoxycortisol can be used as a substrate to prepare cortisone, the yield of the product is high, no by-product is generated, and the P450 enzyme mutant has a good industrial application prospect.

This invention relates to pharmaceutically acceptable salts, entantiomers or diastereomers of novel compounds of the Formula (Im1) wherein R1, R2, R3, A1, Cy1 and E are as defined in the specification, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention furhter relates to pharmaceutical compositions of the pharmaceutically acceptable salts, enantiomers or diastereomers of novel compounds for use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

Described herein are topical compositions containing one or more of an antibacterial, an antifungal, and an anti-inflammatory, for use in supporting the health of a subject, including preventing or treating a fungal infection, a yeast infection, a bacterial infection, inflammation, or any combination thereof. A preferred formulation comprises mupirocin calcium in an amount of about 0.5% v / v, terbinafine hydrochloride in an amount of about 0.25% v / v, clotrimazole in an amount of about 0.25% v / v, and hydrocortisone acetate in an amount of about 0.25% v / v.

The present disclosure relates generally to the treatment of adrenal dysfunction (such as congenital adrenal hyperplasia) with a combination of 2‑thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl (crinecerfont) and certain pharmaceutical compositions of hydrocortisone (such as a delayed release oral pharmaceutical composition of hydrocortisone).

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of methylprednisolone and an intermediate compound thereof. The preparation method comprises the following steps: by taking cortisone as a raw material, carrying out 17 and 21 site upper protecting groups and 3 site upper protecting groups, and carrying out reduction, so as to obtain a methylprednisolone intermediate compound shown as a formula V; and carrying out 5 and 6-site epoxidation, Grignard reaction, 3-site protecting group removal, 4 and 5-site dehydration elimination, 1 and 2-site dehydrogenation and 17 and 21-site protecting group removal on the compound in the formula V to obtain methylprednisolone. The structural formula of the compound of formula V is shown in the specification. The preparation process has the advantages of high yield, high purity, low cost, simplicity in operation and suitability for industrial production.

The application discloses an amplification culture medium and a culture method of human adult epidermal stem cells, and relates to the technical field of stem cell in-vitro culture. The culture medium comprises the following components: fibroblast growth factor, interleukin-6, insulin-like growth factor-1, epidermal growth factor, insulin, growth hormone, hydrocortisone, Y-27632, A83-01, Forsklin, PY60, CHIR99021, linoleic acid, linolenic acid, alanine, asparagine, glutamic acid, glycine, proline, serine, arginine, N-acetyl-L-cysteine, beta-mercaptoethanol and CaCl2. The culture medium can continuously and stably culture human adult epidermal stem cells for more than 20 generations, and a more stable long-term in-vitro amplification system of epidermal stem cells is established. After continuous subculture, the epidermal stem cells can maintain a high proliferation rate and multiple differentiation potential, and have the ability to construct multilayer skin.

The invention provides a culture medium and a culture method of normal oral fibroblasts. The culture medium comprises a DMEM (Dulbecco's Modified Eagle Medium) and the following components based on the volume of the DMEM: 10v% of Australian fetal calf serum, 2.5 ng / ml of bFGF (Basic Fibroblast Growth Factor), 1v% of a penicillin-streptomycin solution, 2.0 ug / ml of hydrocortisone and 0.05 ug / ml of FGF10 (Fibroblast Growth Factor 10). The invention solves the problems of high NF culture difficulty, easy pollution, low survival rate, incapability of permanent passage and the like, provides a basis for further exploring a mechanism for activating the NF into CAFs, is beneficial to finding and finding new therapeutic targets, and provides a new clinical diagnosis and treatment idea for treating and preventing the deterioration of the salivary gland benign tumor.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.